---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-22-036093"
form_type: "8-K/A"
ticker: "LSTA"
cik: "0000320017"
company_name: "LISATA THERAPEUTICS, INC."
filed_at: "2022-10-04T23:59:59+00:00"
generated_at: "2026-06-23T05:43:42.381315+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Lisata provides financials of acquired Cend; CEND-1 in Phase 2b for pancreatic cancer

## Summary
- Merger of Cend into Lisata completed Sep 14, 2022; this amendment provides historical and pro forma financials of Cend.
- Cend's lead drug CEND-1 (iRGD peptide) in Phase 2b for 1L metastatic PDAC; Phase 1b showed promising safety and efficacy.
- Cend collaboration with Qilu Pharma for Greater China: $10M upfront, up to $225M in milestones, tiered royalties 10-15%.
- Cend recorded net income in 2021 from one-time license payment, but otherwise incurred losses since inception.
- Unaudited interim financials of Cend as of June 30, 2022 and pro forma combined financials of Lisata are filed.

## SEC filing metadata
- accession: 0001140361-22-036093
- form_type: 8-K/A
- ticker: LSTA
- cik: 0000320017
- company_name: LISATA THERAPEUTICS, INC.
- filed_at: 2022-10-04T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/320017/000114036122036093/0001140361-22-036093-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/320017/000114036122036093/brhc10042374_8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-22-036093
- JSON: https://secwatch.observer/filing/0001140361-22-036093.json
- Plain text: https://secwatch.observer/filing/0001140361-22-036093.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.